Clinical trials
Progressive Multiple Sclerosis clinical trials
Below are recruiting progressive multiple sclerosis clinical trials, each written for real people, not researchers. We’re tracking 134 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07067463RecruitingPhase 3
Testing orelabrutinib for primary progressive MS
This trial tests a daily pill called orelabrutinib to see if it can slow disability progression in people with primary progressive multiple sclerosis (PPMS). It may be an option for patients whose symptoms have been getting worse over the past two years.
Pheonix, ArizonaAges 18–60 - NCT07299019RecruitingPhase 3
Study of orelabrutinib for secondary progressive MS
This study tests an oral medication called orelabrutinib for people whose multiple sclerosis has changed from relapsing-remitting to secondary progressive. The goal is to see if it can slow down disability worsening that happens even without relapses.
Phoenix, ArizonaAges 18–60 - NCT07282574RecruitingPhase 2
Testing a new study drug for progressive MS
This trial tests a new study drug added to your current MS treatment (ocrelizumab) for people with progressive MS. It aims to see if the combination works better than ocrelizumab alone.
Camperdown, New South WalesAges 18–60 - NCT07325292RecruitingPhase 3
Frexalimab injection vs IV for multiple sclerosis
This study tests if a new injection (frexalimab) works as well as the IV version for people with relapsing or certain types of secondary progressive multiple sclerosis. It could offer a more convenient way to receive this treatment at home.
Cullman, AlabamaAges 18–60 - NCT05704361RecruitingPhase 1
Study of an experimental drug for multiple sclerosis
This study tests an experimental drug called RO7121932 in people with multiple sclerosis. The goal is to see how safe it is and how the body processes it. It might help by offering a new way to manage the condition.
Stanford, CaliforniaAges 18–65 - NCT05285891RecruitingPhase 4
Stopping ocrelizumab in early relapsing multiple sclerosis
This study looks at whether people with early relapsing multiple sclerosis can safely stop ocrelizumab. Researchers will compare health and MRI findings over time to see if stopping helps or increases relapse risk.
New Haven, ConnecticutAges 18–55 - NCT03600779Recruiting
Advanced MRI scan for multiple sclerosis
This study uses a special MRI scan to look at brain damage caused by multiple sclerosis (MS). It may help doctors better understand the disease and could lead to better treatments.
Marseille, PACAAges 18–45 - NCT07587125RecruitingPhase 1
CAR-T Cell Therapy for Progressive Multiple Sclerosis
This trial tests a new cell therapy called S103 for people with MS that isn't responding well to standard treatments. The therapy involves modifying immune cells in the lab and putting them back into your body to help control the disease.
Xi'an, ShaanxiAges 18–75 - NCT07732907Recruiting
Study of PML risk in MS patients taking Zeposia
This study looks at people with multiple sclerosis who have taken Zeposia (ozanimod) and later developed a rare brain infection called PML. The goal is to understand how often this happens and to confirm cases.
Lawrenceville, New JerseyAges Any age - NCT07225504RecruitingPhase 3
Study of remibrutinib for secondary progressive multiple sclerosis
This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.
Birmingham, AlabamaAges 18–65 - NCT03783416RecruitingPhase 1
Ixazomib safety study for people with multiple sclerosis
This early-phase study tests how safe ixazomib is for people with multiple sclerosis (MS). It focuses on targeting certain immune cells in MS and checks whether the treatment can be given safely.
London, Greater LondonAges 18–65 - NCT03900221Recruiting
Pregnancy monitoring registry for multiple sclerosis in France
This study follows people who are pregnant and have multiple sclerosis (or related conditions) to better understand what happens during pregnancy. It does not appear to test a new treatment; it mainly collects health and pregnancy information.
AmiensAges Any age - NCT03910738RecruitingPhase 2
Testosterone treatment for nerve protection and myelin repair in MS
This Phase 2 study tests whether taking testosterone (for low testosterone levels) can help protect nerves and repair myelin in people with relapsing-remitting multiple sclerosis (MS). It may be most relevant if your MS is stable and you have low blood testosterone without current androgen treatment.
BesançonAges 18–55 - NCT03981003Recruiting
Blood tests to track brain and nerve changes in MS
This study measures blood markers (from a serum blood sample) to see how nerve and brain changes relate to MS disease activity and disability over time. It may help researchers better monitor MS, especially in people followed in the OFSEP program.
AmiensAges 15 years+ - NCT04047628RecruitingPhase 3
MS patients with active relapsing disease comparing two treatment plans
This Phase 3 study compares the best standard MS treatment (chosen by your doctors) versus an approach called autologous hematopoietic stem cell transplant (AHSCT) for people with highly active, treatment-resistant relapsing multiple sclerosis. It aims to see which option controls MS disease activity better and keeps you safer over time.
Palo Alto, CaliforniaAges 18–55 - NCT04806568Recruiting
Cognitive training to help brain flexibility in multiple sclerosis
This study tests whether structured cognitive exercises can improve “neuroplasticity,” meaning how flexible and changeable the brain is. It includes people with multiple sclerosis and healthy volunteers, and uses tasks plus brain scans to see what changes over time.
Thessaloniki, Central MacedoniaAges 18–65 - NCT05061953Recruiting
Eye-tracking test software study in adults with multiple sclerosis
This study checks how well new eye-tracking software can measure eye movements in people with multiple sclerosis. It may help researchers track changes in how the nervous system works using a simple camera-based eye test.
Montreal, QuebecAges 18 years+ - NCT05177523Recruiting
MRI study of nerve damage and repair in multiple sclerosis
This trial uses MRI scans to better understand how nerve fibers are damaged and repaired in people with multiple sclerosis. It may help researchers connect scan findings to disease activity and progression.
BaselAges 18–80 - NCT05204459Recruiting
MRI and eye-scan study for MS and related conditions
This trial uses brain MRI and eye imaging tests to study research markers in people with multiple sclerosis (MS) and related neurologic conditions. It may help researchers better understand these diseases and how they change over time.
Los Angeles, CaliforniaAges 18 years+ - NCT05491031Recruiting
MRI scan study to predict disability changes in MS
This study uses MRI scans to predict how quickly disability may worsen in people with multiple sclerosis (MS). It may help doctors spot people at higher risk of progression earlier.
PoitiersAges 18 years+ - NCT05532943RecruitingPhase 1/Phase 2
Cord stem cell treatment for people with multiple sclerosis
This Phase 1/2 trial studies whether donated umbilical cord stem cells are safe and can improve multiple sclerosis. It aims to see if the treatment is workable for people who still have active MS despite standard therapies.
Taichung, Non-USAges 20–65 - NCT05740722RecruitingPhase 2
Nicotinamide riboside for progressive multiple sclerosis
This Phase 2 trial studies whether a vitamin-like supplement called nicotinamide riboside can slow or improve disability in progressive multiple sclerosis. It may help people whose symptoms have been steadily getting worse over the last 2 years.
BergenAges 18–65 - NCT05748015Recruiting
Checking how the nervous system is affected in multiple sclerosis
This study looks at signs of how your automatic “control” nerves (the autonomic nervous system) may be affected in people with multiple sclerosis. It may help researchers better understand different types of MS and how to recognize nervous-system involvement.
Telese Terme, BeneventoAges 18 years+ - NCT05758831RecruitingPhase 3
Rituximab vs ocrelizumab for relapsing multiple sclerosis
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
Lyon, BronAges 18–55
Hear when a new Progressive Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for progressive multiple sclerosis?
- Yes. Clin2 currently lists 134 recruiting progressive multiple sclerosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a progressive multiple sclerosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a progressive multiple sclerosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis (MS) Primary Progressive
- Multiple Sclerosis (MS) Secondary Progressive
- Multiple Sclerosis, Chronic Progressive
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis (MS) - Relapsing-remitting
- Relapsing Multiple Sclerosis
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.